Member Login

ADAPT

Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue


Welcome to the ADAPT Homepage

The work in this project is supported by the European Community’s 7th Framework
Programme under the call FP7-HEALTH-2007-A, SP-1 Cooperation, with contract no. HEALTH-F2-2008-201100. Coordinator: Juergen Eckel, German Diabetes Center

ADAPT is an EC-funded collaborative project of top European laboratories focusing on adipose tissue as a major endocrine organ. The major goal of this project is to identify novel or existing adipocytokines as drug targets that could be used to reverse obesity-associated inflammation and adverse reactions related to excess fat. The mustidisciplinary ADAPT consortium involves 11 partners and integrates basic and clinical science, bioinformatics, and in silico drug design. ADAPT is an inter-European collaborative network involving partners from Germany, Sweden, France and the Czech Republic.

If you are interested in obtaining further information about ADAPT, please contact the coordinator.

ADAPT, Diabetes, Adipokines, Obesity

News

25.04.12

The ADAPT project has been successfully completed on January 31, 2012 and the final report has been...

24.11.11

Final Scientific Meeting

The ADAPT project will be completed on January 31, 2012. To discuss the...

03.05.11

Final Meeting of COST Action BM0602

The final meeting of COST Action BM0602 "Adipose tissue:...

29.04.11

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic...

04.02.11

 

3nd Protein Rainbow Workshop – BioPlex Technology: Multiplicating ELISA

The annual training...

13.08.10

2nd Protein Rainbow Workshop - SELDI for Biomarker Research Düsseldorf, September 06 – 09,...